Johnson & Johnson (NYSE:JNJ) Shares Sold by Powers Advisory Group LLC

Powers Advisory Group LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,558 shares of the company’s stock after selling 211 shares during the period. Johnson & Johnson accounts for about 0.9% of Powers Advisory Group LLC’s portfolio, making the stock its 24th largest holding. Powers Advisory Group LLC’s holdings in Johnson & Johnson were worth $1,498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Hibernia Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $37,000. Tower View Wealth Management LLC grew its stake in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Creative Capital Management Investments LLC grew its stake in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $48,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $177.31.

Johnson & Johnson Trading Up 1.4 %

NYSE JNJ opened at $157.96 on Thursday. The stock has a market capitalization of $380.65 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The firm has a 50-day moving average price of $158.76 and a 200 day moving average price of $156.69. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.35 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.